Post by dividavi on Aug 6, 2022 21:25:36 GMT
Brief excerpt:
Click on tweet for full article.
This is certainly not the first time the US FDA, which approves new drugs and medical devices, has come under scrutiny.
Recently, its controversial decision to approve a new drug for Alzheimer's disease sparked an outcry from health professionals who claimed industry-led clinical trials had not yet demonstrated the antibody therapy – now on the market for around US$56,000 per year – would slow memory loss or cognitive decline.
Recently, its controversial decision to approve a new drug for Alzheimer's disease sparked an outcry from health professionals who claimed industry-led clinical trials had not yet demonstrated the antibody therapy – now on the market for around US$56,000 per year – would slow memory loss or cognitive decline.